Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Pemetrexed After Pemetrexed Plus Nedaplatin in Advanced Lung Adenocarcinoma
ChiCTR-OIC-17011634Phase 2Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and nedaplatin in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: response rate. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
pemetrexednedaplatin
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OIC-17011634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011634.